| (Values in U.S. Thousands) | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 | Mar, 2021 |
| Sales | 84,040 | 56,630 | 34,160 | 32,260 | 25,380 |
| Sales Growth | +48.40% | +65.78% | +5.89% | +27.11% | +41.08% |
| Net Income | -4,310 | 20,110 | 3,560 | 8,900 | 5,090 |
| Net Income Growth | -121.43% | +464.89% | -60.00% | +74.85% | +327.23% |
Elite Pharma Inc
(ELTP)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Elite Pharmaceuticals, Inc. primarily engages in researching, developing, licensing, manufacturing, and marketing proprietary drug delivery systems and products. Their drug delivery technology involves releasing a drug into the bloodstream or delivering it to a target site in the body over an extended period of time or at predetermined times.
Fiscal Year End Date: 03/31